We are live on
!
Find out more
AA
AlphaCentric Advisors Portfolio holdings
AUM
$100M
This Fund
S&P 500
This Quarter
Est. Return
+8.22%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$100M
AUM Growth
–
Cap. Flow
+$100M
Cap. Flow
% of AUM
100.06%
Top 10 Holdings %
Top 10 Hldgs %
20.66%
Holding
249
New
249
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$2.64M |
| 2 |
Invitation Homes
INVH
|
+$2.51M |
| 3 |
iShares MBS ETF
MBB
|
+$2.48M |
| 4 |
Euronet Worldwide
EEFT
|
+$2.17M |
| 5 |
Vertex Pharmaceuticals
VRTX
|
+$2.01M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 40.96% |
| 2 | Technology | 10.32% |
| 3 | Real Estate | 9.94% |
| 4 | Industrials | 7.65% |
| 5 | Financials | 4.84% |
Similar funds
WCM
FCM
BIA
AGAM
E
HCM
AC
OIS
AlphaCentric Advisors's Q4 2025 Portfolio in Review
Q4 2025 is the first quarter with a 13F filing on record for AlphaCentric Advisors, which disclosed 249 positions worth $100M. Its ten largest holdings account for 21% of the portfolio.
Its largest position is Gilead Sciences: 21,761 shares worth $2.67M.
By sector, the portfolio is most concentrated in Healthcare at 41% of assets, followed by Technology and Real Estate.
- AlphaCentric Advisors's largest Q4 2025 buy was Gilead Sciences: 21,761 shares worth $2.67M.
- AlphaCentric Advisors's ten largest holdings make up 21% of its $100M portfolio in Q4 2025.
- AlphaCentric Advisors disclosed 249 positions in Q4 2025, its first 13F filing on record.
Based on AlphaCentric Advisors's 13F filing for Q4 2025, filed 12 Feb 2026.